Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10817816 | 0.81 | SLC2A1 (0.59) | SLC2A1HTTPTK2MAPTTGFBR1 | |
| SCHEMBL10803018 | 0.81 | SLC2A1 (0.52) | SLC2A1HTTPTK2MAPTNQO2 | |
| SCHEMBL10805234 | 0.78 | SLC2A1 (0.74) | SLC2A1HTTMAPTTGFBR1L3MBTL1 | |
| SCHEMBL10804993 | 0.78 | SLC2A1 (0.49) | SLC2A1HTTPTK2NQO2 | |
| SCHEMBL10507503 | 0.78 | CYP2C19 (0.52) | SLC2A1HTTPTK2NQO2KDM4E | |
| SCHEMBL10801863 | 0.78 | SLC2A1 (0.70) | SLC2A1HTTMAPTL3MBTL1KDM4E | |
| SCHEMBL20272422 | 0.77 | SLC2A1 (0.47) | SLC2A1HTTPTK2MAPTKDM4E | |
| SCHEMBL10506617 | 0.77 | SLC2A1 (0.48) | SLC2A1HTTPTK2MAPTCYP3A4 | |
| SCHEMBL10801118 | 0.77 | SLC2A1 (0.48) | SLC2A1HTTNQO2 | |
| SCHEMBL10803203 | 0.77 | SLC2A1 (0.57) | SLC2A1MAPTL3MBTL1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | SLC2A1 3888/4885HTT 4376/4885PTK2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.